Chief Executive Officer and Director
B App Sci and Grad Dip Marketing
Bernie Romanin has extensive healthcare experience in Diagnostics, Pharmaceuticals, Healthcare Bioinformatics and Medical Devices gained in Australia and internationally including commercial expertise (sales, marketing and business development) spanning more than 35 years.
During almost a decade in the USA with Chiron, Novartis and Bayer he has directed market development activities to identify, validate and commercialise new opportunities in diagnostics in the areas of Infectious Diseases (Hepatitis and HIV/AIDS), Oncology, Cardiovascular Disease and Metabolic Disorders.
Bernie has significant experience in managing start-up and new market business opportunities particularly in Technology Licensing and Partnerships and broad experience in managing a multi-functional organisation including R&D, sales and marketing, business development and market research.
Dr. Robyn A. Lindley
Chief Scientific Officer and Director
Inventor and Developer of the TSM Platform.
BSc, MInfoTech, PhD
Dr. Robyn A. Lindley is Science Director, and an Honorary Senior Fellow in the Department of Pathology, Faculty of Medicine, Dentistry and Health Sciences at the University of Melbourne in Australia. Although her first degrees are in physics and informatics, Robyn is an immunogeneticist who has been publishing on the molecular mechanisms of evolution and somatic hypermutation for almost two decades.
Robyn has been credited as a co-discoverer of the first data-driven evidence showing that the immunoglobulin somatic hypermutation process involves an mRNA intermediate, and that the strand-bias mutation signatures generated during somatic hypermutation of immunoglobulin genes, are evident in several cancers. She is the sole discoverer of the specific codon-contexted targeted somatic mutation (TSM) signatures of nucleotide-specific deaminase enzymes that are now heavily implicated in many cancers.
More recently, Robyn has developed methods to identify the inferred deaminase binding domains of enzymes that predict recurrence of cancer. She is turning these foundation discoveries into new genetic tests.
Chief Financial Officer and Company Secretary
Bachelor of Business (Accounting/Corporate Law)
Melanie Leydin holds a Bachelor of Business majoring in Accounting and Corporate Law. She is a member of the Institute of Chartered Accountants and is a Registered Company Auditor. She graduated from Swinburne University in 1997, became a Chartered Accountant in 1999 and since February 2000 has been the principal of Chartered Accounting and Corporate Secretarial firm, Leydin Freyer. The practice provides outsourced company secretarial and accounting services to public and private companies across a host of industries including but not limited to the Resources, technology, bioscience, biotechnology and health sectors. Melanie has over 25 years’ experience in the accounting profession and has extensive experience in relation to public company responsibilities, including ASX and ASIC compliance, control and implementation of corporate governance, statutory financial reporting, reorganisation of Companies and shareholder relations.
Dr. Nathan Hall
Dr. Nathan Hall is an accomplished researcher with expertise in bioinformatics, computational biology and genomics sciences. His background is in biomedical research, starting out his career over twenty years ago when genomes were only beginning to be sequenced. Nathan collaborates widely and is published in areas such as Cancer research and genomic analyses.
Nathan understands the importance of integrating computational biology with medical and scientific research to maximise the benefits of modern sequencing technologies. With this understanding of the power of genomic technology, Nathan is engaging with Medical Practitioners, laboratory scientist and researchers, and computational professionals to bring together a platform for genomic testing moving into the future.
Dr. Jared Mamrot
BSc(Hons), MCE, PhD
Dr. Mamrot is a bioinformatician/data scientist who completed his PhD in developmental genomics at the Hudson Institute of Medical Research in Victoria, Australia. He has experience developing novel computational pipelines and applying innovative methods to complex biological challenges. He is an active member of the scientific community and is an ambassador for reproducibility and open science initiatives for the journal eLife and protocols.io.
At GMDx, he is applying state-of-the-art artificial intelligence / machine learning methods to drive scientific advances in immunology and oncology. He is currently heading the machine learning program developing novel approaches to predict patient response to treatments for many diseases.
Mr. Terry Sinclair
Terry has more than 30 years of diverse leadership experience in network and technology enabled business models, including those in highly regulated industry sectors and with operations across Asia Pacific. This includes listed companies, private equity and government related entities.
He currently serves as a Non-Executive Director of Cleanaway Limited
[ASX :CWY], Ovato Limited [ASX:OVT], and Zoom2U Pty Ltd . His recent roles include Strategic Advisor to KPMG, Transaction Advisor to The Carlyle Group in relation to the acquisition of platform based alternative infrastructure, leading a privately funded disruptive technology start-up to commercialisation as Executive Chairman/ CEO, through to Chairman of a privately owned high growth/ roll up to IPO in the domestic logistics sector.
Mr. Greg Johnson
Independent Non-Executive Director
Greg joined Diabetes Victoria as Chief Executive in January 2003. He was Acting Chief Executive of Diabetes Australia from July 2009 to February 2011 and was appointed permanently in November 2012.
He has over 25 years experience in healthcare leadership in CEO and Board roles and has lived and worked in NSW, Victoria, SA and Tasmania.
He is an Adjunct Professor with Deakin University and holds a degree in pharmacy, post-graduate qualifications in hospital pharmacy and health service management, and a masters degree in business administration.
He has participated in a wide range of health industry and government advisory committees and has a particular interest in prevention and has led the establishment of a number of leading diabetes prevention initiatives.
Mr. Stephen Moulton
Independent Non-Executive Director
Stephen is a Partner at Gadens lawyers in the Corporate Team, specialising in Mergers & Acquisitions. In addition, he has extensive experience in corporate and commercial advice, employee share schemes and financial services.
Prior to joining Gadens, Stephen was a partner at Clayton Utz and PricewaterhouseCoopers, and before that was the chairman of partners and a former managing partner of Mills Oakley Lawyers, where he founded the corporate practice. Stephen is a Chairman of the O’Brien Foundation and a former director of Carlton Football Club.